INVESTIGADORES
OLIVERA Maria Eugenia
congresos y reuniones científicas
Título:
EFFICACY AND PHARMACOKINETICS OF CIPROFLOXACIN-ALUMINUM COMPLEX (CIP-Al) AND CIP IN MOUSE
Autor/es:
BREDA A; GONZALEZ C; CONFALONIERI AMANZO R; SANCHEZ BRUNI S; MANZO R; OLIVERA M
Lugar:
Rosario, Santa Fé
Reunión:
Congreso; 41 Reunión Anual de La Asociación Argentina de Farmacologia Experimental- SAFE; 2009
Institución organizadora:
Asociación Argentina de Farmacologia Experimental- SAFE
Resumen:
<!--
/* Font Definitions */
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:-1610611985 1073750139 0 0 159 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:Calibri;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:"Times New Roman";
mso-ansi-language:ES-TRAD;
mso-fareast-language:EN-US;}
@page Section1
{size:595.3pt 841.9pt;
margin:70.85pt 3.0cm 70.85pt 3.0cm;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
The aim of this study was to determine the pharmacokinetics of CIP-Al in
comparison with CIP and their efficacy in an experimental Salmonella infection
model in mouse, determined by reduced mortality after treatment. For antibiotic
efficacy BALB/c mouse were divided into 3 groups: no treatment, CIP and CIP-Al.
After 5 days of treatment survival was recorded. Single-dose pharmacokinetics
of orally administered drugs was determined in whole blood and in lung,
intestine and kidney tissue, which were assayed by means of the HPLC method
with fluorescence detection. In the efficacy study, treatment with CIP-Al
reduced mortality in a higher percentage, however differences were not
significant. In the pharmacokinetics study, AUC values for CIP and CIP-Al were
similar. In contrast, CIP levels in lung, intestine and kidney tissue after
CIP-Al administration were much higher than those of CIP group. Besides, Cmax
was significantly higher and tmax significantly lower in the CIP-Al group. The
higher plasma and tissue concentrations of CIP-Al may have contributed to the
observed efficacy tendency. This fact would be related to the improved aqueous
compatibility of CIP after aluminum complexation. We found that CIP-Al is at
least as effective as CIP and exhibited advantageous pharmacokinetic and
dispositional properties. It may become a valuable asset based on its
formulation versatility due to higher solubility.
